Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (71-80 of 247) with videos related to

Pageof 25
Sort By:
Investigational New Drugs|August 4, 2018
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitorJames J Harding, Todd M Bauer, Daniel S W Tan, et al.
Veterinary Pathology|December 27, 2021
Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic miceEnric Vidal, Carlos López-Figueroa, Jordi Rodon, et al.
Cancers|August 23, 2020
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and ParagangliomasCamilo Jimenez, Vivek Subbiah, Bettzy Stephen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C Bendell, Jordi Rodon, Howard A Burris, et al.
Investigational New Drugs|March 7, 2020
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant gliomaAntje Wick, Annick Desjardins, Cristina Suarez, et al.
The Oncologist|June 13, 2023
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid TumorsBlessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, et al.
Journal of Gastrointestinal Cancer|April 29, 2023
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical TrialsRishi Surana, Graciela Nogueras Gonzalez, Jane Rogers, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2008
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic studyJordi Rodon, Mitchell Garrison, Lisa A Hammond, et al.
Cancers|August 12, 2022
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical TrialsJeffrey A How, Amir A Jazaeri, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumorsGeoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, et al.
Pageof 25

Showing results (71-80 of 247) with videos related to

Sort By:
Pageof 25
Investigational New Drugs|August 4, 2018
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitorJames J Harding, Todd M Bauer, Daniel S W Tan, et al.
Veterinary Pathology|December 27, 2021
Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic miceEnric Vidal, Carlos López-Figueroa, Jordi Rodon, et al.
Cancers|August 23, 2020
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and ParagangliomasCamilo Jimenez, Vivek Subbiah, Bettzy Stephen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C Bendell, Jordi Rodon, Howard A Burris, et al.
Investigational New Drugs|March 7, 2020
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant gliomaAntje Wick, Annick Desjardins, Cristina Suarez, et al.
The Oncologist|June 13, 2023
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid TumorsBlessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, et al.
Journal of Gastrointestinal Cancer|April 29, 2023
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical TrialsRishi Surana, Graciela Nogueras Gonzalez, Jane Rogers, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2008
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic studyJordi Rodon, Mitchell Garrison, Lisa A Hammond, et al.
Cancers|August 12, 2022
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical TrialsJeffrey A How, Amir A Jazaeri, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumorsGeoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, et al.
Pageof 25